Ultrapurified Phospholipoproteomic Composition for High-Purity Biomolecular Research and Precision Therapeutics
AssigneeAetherion Global LLC
InventorRamon E. Gutierrez-Sandoval
Life of this patent
Estimating the term…
Loading patent…
AssigneeAetherion Global LLC
InventorRamon E. Gutierrez-Sandoval
Estimating the term…
The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.
A phospholipoproteomic composition, characterized by the presence of:
Dependencies are inferred from the claim text.